Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery

Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuticals industry turns its attention to precision medicine — the search...
Andreessen Horowitz hires Julie Yoo as general partner

Andreessen Horowitz hires Julie Yoo as general partner

Julie Yoo has joined Andreessen Horowitz as its newest general partner. She will make investments out of the venture capital firm’s bio fund, which closed on $450 million in 2017. Yoo spent the last eight years as a co-founder and chief product officer of Kyruus, a...